Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2016

04.04.2016 | Clinical trial

Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population

verfasst von: Seung Taek Lim, Jung Eun Choi, Sei Joong Kim, Hyun Ah Kim, Ji Young Kim, Heung Kyu Park, Young Jin Suh

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have not considered the axillary lymph node status when investigating the prognostic role of tumor location according to each molecular subtype. The present study aimed to investigate the prognostic implication of tumor location according to each molecular subtype in Korean invasive ductal carcinoma (IDC) patients with axillary lymph node metastasis. Data from 7856 Korean IDC women with axillary lymph node metastasis were retrospectively analyzed. According to tumor location, patients were divided into the following groups: upper-outer quadrant, lower-outer quadrant, upper-inner quadrant, lower-inner quadrant (LIQ), and central group. Overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated according to tumor location and molecular subtype. A subgroup analysis based on tumor size categorization was also performed. The patients’ mean age was 47.97 ± 9.64 years, and the median follow-up time was 90 months. The LIQ group showed significantly worse prognosis in OS and BCSS (76.4 and 83.3 %, respectively) compared with the other groups, which was only significant in human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative (TN) subtypes. In the subgroup analysis according to tumor size, the LIQ group showed a significantly worse prognosis in OS and BCSS compared with the other groups, in HER2 and TN subtypes, and only in patients with more than T2 stage. In Korean IDC patients with axillary lymph node metastasis, LIQ tumor location was associated with poor prognosis among those with HER2 and TN molecular subtypes and especially in those with more than T2 stage.
Literatur
1.
Zurück zum Zitat Toikkanen S, Pylkkänen L, Joensuu H (1967) Invasive lobular carcinoma of the breast had better short- and long- survival than invasive ductal carcinoma. Br J Cancer 76:1234–1240CrossRef Toikkanen S, Pylkkänen L, Joensuu H (1967) Invasive lobular carcinoma of the breast had better short- and long- survival than invasive ductal carcinoma. Br J Cancer 76:1234–1240CrossRef
2.
Zurück zum Zitat Nemoto T, Vana J, Bedwani RN et al (1980) Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45:2917–2924CrossRefPubMed Nemoto T, Vana J, Bedwani RN et al (1980) Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45:2917–2924CrossRefPubMed
3.
Zurück zum Zitat Biglia N, Maggiorotto F, Liberale V et al (2013) Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Sur Oncol 39:455–460CrossRef Biglia N, Maggiorotto F, Liberale V et al (2013) Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Sur Oncol 39:455–460CrossRef
4.
Zurück zum Zitat Garne JP, Aspegren K, Linell F et al (1994) Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade. Cancer 73:1438–1448CrossRefPubMed Garne JP, Aspegren K, Linell F et al (1994) Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade. Cancer 73:1438–1448CrossRefPubMed
5.
Zurück zum Zitat Sarp S, Fioretta G, Verkooijen HM et al (2007) Tumor location of the lower-inner quadrant is associated with an impaired survival for women with early-stage breast cancer. Ann Surg Oncol 14:1031–1039CrossRefPubMed Sarp S, Fioretta G, Verkooijen HM et al (2007) Tumor location of the lower-inner quadrant is associated with an impaired survival for women with early-stage breast cancer. Ann Surg Oncol 14:1031–1039CrossRefPubMed
6.
Zurück zum Zitat Wu S, Zhou J, Ren Y et al (2014) Tumor location is a prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer. Int J Surg 12:394–398CrossRefPubMed Wu S, Zhou J, Ren Y et al (2014) Tumor location is a prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer. Int J Surg 12:394–398CrossRefPubMed
7.
Zurück zum Zitat Lohrisch C, Jackdon J, Jones A et al (2000) Relationship between tumor location and relapse in 6781 women with early invasive breast cancer. J Clin Oncol 18:2828–2835PubMed Lohrisch C, Jackdon J, Jones A et al (2000) Relationship between tumor location and relapse in 6781 women with early invasive breast cancer. J Clin Oncol 18:2828–2835PubMed
8.
Zurück zum Zitat Colleoni M, Zahrieh D, Gelber RD et al (2005) Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol 23:1390–1400CrossRefPubMed Colleoni M, Zahrieh D, Gelber RD et al (2005) Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol 23:1390–1400CrossRefPubMed
9.
Zurück zum Zitat Montagna E, Bagnardi V, Rotmensz N et al (2015) Outcome and medial presentation of breast cancer: European Institute Of Oncology Experience. Clin Breast Cancer 15:440–447CrossRefPubMed Montagna E, Bagnardi V, Rotmensz N et al (2015) Outcome and medial presentation of breast cancer: European Institute Of Oncology Experience. Clin Breast Cancer 15:440–447CrossRefPubMed
10.
Zurück zum Zitat Yu J, Li G, Li J et al (2005) The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys 61:874–878CrossRefPubMed Yu J, Li G, Li J et al (2005) The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys 61:874–878CrossRefPubMed
11.
Zurück zum Zitat Klauber-DeMore N, Bevilacqua JL, Van Zee KJ et al (2001) Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 193:547–555CrossRefPubMed Klauber-DeMore N, Bevilacqua JL, Van Zee KJ et al (2001) Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 193:547–555CrossRefPubMed
12.
Zurück zum Zitat Veronesi U, Cascinelli N, Bufalino R et al (1983) Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 198:681–684CrossRefPubMedPubMedCentral Veronesi U, Cascinelli N, Bufalino R et al (1983) Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 198:681–684CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Yao MS, Kurland BF, Smith AH et al (2007) Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Ann Surg Oncol 14:2985–2993CrossRefPubMed Yao MS, Kurland BF, Smith AH et al (2007) Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Ann Surg Oncol 14:2985–2993CrossRefPubMed
14.
Zurück zum Zitat Moon HG, Han W, Noh DY (2009) Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol 27:5899–5905CrossRefPubMed Moon HG, Han W, Noh DY (2009) Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol 27:5899–5905CrossRefPubMed
16.
Zurück zum Zitat González-soto MJ, Bajén MT, Pla MJ et al (2006) Influence of tumor location in patients with breast cancer on the sentinel node detection. Rev Esp Med Nucl 25:98–102CrossRefPubMed González-soto MJ, Bajén MT, Pla MJ et al (2006) Influence of tumor location in patients with breast cancer on the sentinel node detection. Rev Esp Med Nucl 25:98–102CrossRefPubMed
17.
Zurück zum Zitat Munñoz M, Fernández-Aceñero MJ, Martín S et al (2009) Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet 280:43–48CrossRef Munñoz M, Fernández-Aceñero MJ, Martín S et al (2009) Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet 280:43–48CrossRef
18.
Zurück zum Zitat Huang O, Wang L, Shen K et al (2008) Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 107:379–387CrossRefPubMed Huang O, Wang L, Shen K et al (2008) Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 107:379–387CrossRefPubMed
19.
Zurück zum Zitat Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomized trials. Lancet 366:2087–2106CrossRefPubMed Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomized trials. Lancet 366:2087–2106CrossRefPubMed
20.
Zurück zum Zitat Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMed Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMed
21.
Zurück zum Zitat Allott EH, Cohen SM, Geradts J et al (2016) Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiol Biomark Prev 25:470–478CrossRef Allott EH, Cohen SM, Geradts J et al (2016) Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiol Biomark Prev 25:470–478CrossRef
Metadaten
Titel
Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population
verfasst von
Seung Taek Lim
Jung Eun Choi
Sei Joong Kim
Hyun Ah Kim
Ji Young Kim
Heung Kyu Park
Young Jin Suh
Publikationsdatum
04.04.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3771-6

Weitere Artikel der Ausgabe 3/2016

Breast Cancer Research and Treatment 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.